Seed · Healthtech · Cambridge, United Kingdom · Founded 2017 · 11–50 employees
Cambridge Cancer Genomics develops AI-driven blood-based diagnostics to track cancer treatment responses, aiming to detect relapse earlier, predict therapy response and shorten ineffective regimens. It raised approximately $4.5 million in a seed round in December 2018 and was subsequently acquired by Dante Labs in June 2021, marking a significant exit. The company was founded in 2017 and maintained a headcount of 11–50 employees during its independent phase. It participated in the Merck Accelerator and Y Combinator programmes, reflecting strong validation from reputable incubators.
No open roles listed right now.